Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
S. Chiba(Tokyo Medical University), Yoshihiro Kawaoka(University of Wisconsin–Madison), Shun Iida(National Institute of Infectious Diseases), Tadaki Suzuki(National Institute of Infectious Diseases), Kiyoko Iwatsuki‐Horimoto(Tokyo University of Science), Yuko Sato(National Institute of Infectious Diseases), Makoto Kuroda(National Institute of Infectious Diseases), Moe Okuda(The University of Tokyo), Masaki Imai(Kobe University), Maki Kiso(Tokyo University of Science), Tammy Armbrust(University of Wisconsin–Madison), Peter Halfmann(University of Wisconsin–Madison), Noriko Nakajima(National Institute of Infectious Diseases), Mutsumi Ito(Tokyo University of Science), Ralph S. Baric(University of North Carolina at Chapel Hill), Tokiko Watanabe, Tadashi Maemura(University of Wisconsin–Madison)
Cited by 32
Related Papers
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets
|Nature|2012|1.5k
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus
|Nature|2007|939
Animal models for COVID-19
|Nature|2020|877